Abstract
Multiple lines of evidence shows that tumorigenesis is often associated with altered carbohydrate metabolism, characterized by increased glucose uptake and elevated glycolysis, which was first recognized by Otto Warburg 70 years ago. Therefore, the inhibition of glycolysis has been proposed as a therapeutic strategy for cancer treatment. However, this disordered glycotic process does not represent the whole picture of altered energy metabolism during cancer cell transformation. In order to achieve rapid cell proliferation, tumor cells have to constantly accumulate large amount of macromolecules for replication, which has led to several hallmarks of cancer demonstrating its robust metabolic adaptation, including high levels of aerobic glycolysis rate, high rate of energy-consuming processes for syntheses of proteins, DNA and fatty acids. This review summarizes some potential drugable targets as well as their pharmacological inhibitors in glucose, glutamine and fatty acid metabolic pathways. In addition, the upstream oncogenic signaling pathways that are tightly in conjunction with the altered metabolism in tumors are also covered.
Keywords: Tumor energy metabolism, glucose, glutamine, fatty acid, oncogenic signals, metabolic interference
Current Medicinal Chemistry
Title: Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Volume: 16 Issue: 13
Author(s): Huaming Sheng, Ben Niu and Hongbin Sun
Affiliation:
Keywords: Tumor energy metabolism, glucose, glutamine, fatty acid, oncogenic signals, metabolic interference
Abstract: Multiple lines of evidence shows that tumorigenesis is often associated with altered carbohydrate metabolism, characterized by increased glucose uptake and elevated glycolysis, which was first recognized by Otto Warburg 70 years ago. Therefore, the inhibition of glycolysis has been proposed as a therapeutic strategy for cancer treatment. However, this disordered glycotic process does not represent the whole picture of altered energy metabolism during cancer cell transformation. In order to achieve rapid cell proliferation, tumor cells have to constantly accumulate large amount of macromolecules for replication, which has led to several hallmarks of cancer demonstrating its robust metabolic adaptation, including high levels of aerobic glycolysis rate, high rate of energy-consuming processes for syntheses of proteins, DNA and fatty acids. This review summarizes some potential drugable targets as well as their pharmacological inhibitors in glucose, glutamine and fatty acid metabolic pathways. In addition, the upstream oncogenic signaling pathways that are tightly in conjunction with the altered metabolism in tumors are also covered.
Export Options
About this article
Cite this article as:
Sheng Huaming, Niu Ben and Sun Hongbin, Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies, Current Medicinal Chemistry 2009; 16 (13) . https://dx.doi.org/10.2174/092986709788186255
DOI https://dx.doi.org/10.2174/092986709788186255 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
AKT Signaling in Regulating Angiogenesis
Current Cancer Drug Targets Peroxisome Proliferator-Activated Receptors and their Ligands in Cancer Drug- Resistance: Opportunity or Challenge
Anti-Cancer Agents in Medicinal Chemistry New Insights Toward Nanostructured Drug Delivery of Plant-Derived Polyphenol Compounds: Cancer Treatment and Gene Expression Profiles
Current Cancer Drug Targets Clinical Management of Diabetes Mellitus in the Older Adult Patient
Current Diabetes Reviews Calorie Restriction and Dietary Restriction Mimetics: A Strategy for Improving Healthy Aging and Longevity
Current Pharmaceutical Design FADS1 is a Prognostic Biomarker in Bladder Cancer: A Study Based on TCGA Data
Combinatorial Chemistry & High Throughput Screening Application of Chiral α-Monofluorocarbonyl Compounds to Analytical and Medicinal Chemistry
Current Organic Chemistry Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry Editorial [Hot Topic: Anti-Lipogenesis as a Novel Strategy for Cancer Therapy (Guest Editors: Jianghua Liu and Deliang Cao)]
Recent Patents on Anti-Cancer Drug Discovery Electrically-Assisted Nucleic Acids Delivery to Tissues In Vivo: Where Do We Stand?
Current Pharmaceutical Design Trifluoroibuprofen Inhibits α-Methylacyl Coenzyme A Racemase (AMACR/P504S), Reduces Cancer Cell Proliferation and Inhibits in vivo Tumor Growth in Aggressive Prostate Cancer Models
Anti-Cancer Agents in Medicinal Chemistry MicroRNA: Biogenesis, Function and Role in Cancer
Current Genomics Kruppel-Like Factors 4 and 5: Unity in Diversity
Current Genomics Tachykinins and the Cardiovascular System
Current Drug Targets Efficient Growth Inhibition of Human Osteosarcoma Cells Using a Peptide Derived from the MDM-2-Binding Site of p53
Protein & Peptide Letters A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Natural Products in Drug Discovery - Concepts and Approaches for Tracking Bioactivity
Current Organic Chemistry The Use of Biomarkers for Bladder Cancer Diagnosis and Surveillance
Mini-Reviews in Medicinal Chemistry Plant Extracts and Isolated Compounds Reduce Parameters of Oxidative Stress Induced by Heavy Metals: An up-to-Date Review on Animal Studies
Current Pharmaceutical Design